Mapping brain functions using electric stimulation during surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how electric impulses delivered during awake surgery for low-grade infiltrative gliomas affect brain function. Twelve patients will undergo surgery at the CHU of Montpellier, where their brain activity will be monitored using electroencephalography and electrocorticography before and after tumor resection. The goal is to analyze the propagation of these electric impulses and identify the neural networks that are inhibited. Data will be processed and analyzed using specialized software to enhance our understanding of brain function mapping.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient carrier of a low-rank infiltrative glioma (OMS Type II) and presenting the indications to benefit from a surgical care in condition awakened for the first time.
* Patient capable of understanding the nature, the purpose and the methodology of the research.
* Having signed an informed consent writes before the inclusion in the research.
* Membership or beneficiary of a national insurance scheme

Exclusion Criteria:

* Systematic pathology with neurological appearance
* Psychiatric disorders
* History of psychotic disorders
* History of cranial trauma serious (according to the classification), previous or evolutionary other neurological pathology
* Major protected by the law (supervision or guardianship)
* Loss of liberty by court or administrative order

Where it's running

• CHU de Montpellier - Service de neurochirurgie
  Montpellier, France Recruiting

Study contacts

• Principal investigator: Hugues DUFFAU, Professor — Department of neurosurgery, Hospital Gui de Chauliac, Montpellier
• Study coordinator: BARBAS Sandrine
• Email: s-barbas@chu-montpellier.fr

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient experiences during treatment for IDH‑mutant grade 2 gliomas: vorasidenib, radiotherapy, or observation

  This project will test how adults with IDH‑mutant grade 2 gliomas feel—their quality of life, treatment symptoms, and anxiety—when they receive vorasidenib, radiotherapy, or active surveillance.

  Recruiting Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Milan · NCT07547163

• Laser thermal therapy for young people with low-grade glioma

  This research will test whether laser interstitial thermal therapy (LITT) can stop or slow recurrent or progressive low-grade gliomas in children, adolescents, and young adults.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07506239

• Dabrafenib and trametinib dose-reduction for BRAF V600 low-grade glioma

  This trial tries to see if stopping or slowly lowering dabrafenib and trametinib after about 12–24 months works for people with BRAF V600–mutant low-grade glioma.

  Recruiting at 12 sites Phase 2 University of California, San Francisco · Birmingham, Alabama and 11 other locations · NCT07110246

• Vorasidenib plus tumor-specific peptide vaccine for recurrent IDH1-mutant lower-grade glioma

  This will test whether combining the oral drug vorasidenib with a tumor-specific peptide vaccine helps adults with recurrent IDH1-mutant lower-grade glioma.

  Recruiting Phase 1 Duke University · Durham, North Carolina · NCT05609994

• Evaluating a new imaging method for low-grade brain tumors in children

  This study is testing a new imaging method to see if it can help doctors better monitor and manage low-grade brain tumors in children.

  Recruiting Early Phase 1 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT05555550

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.